PharmAust opens state-of the-art new Lab in Perth

ASX listed anti-cancer crusader PharmAust this month moved into a state-of –the-art new laboratory in Technology Park, Perth.

The new laboratory, which is operated by PharmAust 100% subsidiary Epichem, is twice as large as the company’s previous lab at Murdoch University.

Epichem's Managing Director, Dr Wayne Best, said "Not only does the new laboratory provide significant extra capacity but its improved design offers significant improvements in efficiency". The timing couldn't be better for the expansion. With most of Epichem's business being for the export market, the current low Australian Dollar adds significantly to our competitiveness and profitability."

Epichem's team of medicinal chemists are also supporting PharmAust's oncology programmes and have made a number of novel analogues of PPL-1, the company’s anti-cancer drug.

While still at the early pre-clinical research stage, if successful, the company says its research could ultimately lead to a new drug with improved properties which is wholly owned by PharmAust.

PharmAust recently completed a ‘first in man” clinical trial held at the Royal Adelaide Hospital and according to the company their anti-cancer drug had showed “meaningful suppression” of a key cancer marker. 

PharmAust (PAA)

Share Price

Closing price for the last 90 trading days
Powered by Morningstar ®

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Powered by Morningstar ®

Company Documents